Immunotherapy shows promise in controlling advanced breast cancer
NCT ID NCT02411656
First seen Jan 24, 2026 · Last updated May 08, 2026 · Updated 14 times
Summary
This study tests whether the immunotherapy drug pembrolizumab can help control advanced breast cancer in patients whose disease has not worsened after initial chemotherapy. It includes 71 adults with either inflammatory breast cancer or triple-negative breast cancer that has spread. The main goal is to see how many patients remain stable or improve within 4 months of starting treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.